US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Spdr S&P Pharmaceuticals Etf

64.65

+1.021.60%

Post-market: 64.55-0.1000-0.15%19:30 EDT

Volume:82.54K

Turnover:5.32M

Market Cap:468.73M

PE:25.04

High:65.03

Open:63.64

Low:63.54

Close:63.63

52wk High:74.35

52wk Low:46.90

Shares:7.25M

Float Shares:7.25M

Volume Ratio:0.24

T/O Rate:1.14%

Dividend:0.27

Dividend Rate:0.42%

EPS(TTM):2.58

EPS(LYR):-0.1280

ROE:42.40%

ROA:0.26%

PB:1.09

PE(LYR):-505.01

Loading ...

Overview Company News Filings

Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained

Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment

Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion

Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars

BMO starts Exelixis at Market Perform into patent cliff

AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape

HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/XPH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"Spdr S&P Pharmaceuticals Etf","latestPrice":64.65,"timestamp":1791576000000,"preClose":63.63,"halted":0,"volume":82544,"hourTrading":{"tag":"盘后","latestPrice":64.55,"preClose":64.65,"latestTime":"19:30 EDT","volume":202,"amount":13070.8525,"timestamp":1791588604201,"change":-0.1,"changeRate":-0.001547,"amplitude":0.001547},"delay":0,"changeRate":0.01603017444601608,"floatShares":7250270,"shares":7250270,"eps":2.581957,"marketStatus":"Market Closed","change":1.02,"latestTime":"10-09 16:00:00 EDT","open":63.64,"high":65.03,"low":63.54,"amount":5319674.37232,"amplitude":0.023417,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.63,"sharesOutstanding":5750270,"nav":64.692928,"aum":465806548.69,"dividendRate":0.004232,"bidAskSpread":0.001894,"preHourTrading":{"tag":"盘前","latestPrice":64,"preClose":63.63,"latestTime":"08:27 EDT","volume":50,"amount":3200,"timestamp":1791548837841,"change":0.37,"changeRate":0.005815,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":64.55,"preClose":64.65,"latestTime":"19:30 EDT","volume":202,"amount":13070.8525,"timestamp":1791588604201,"change":-0.1,"changeRate":-0.001547,"amplitude":0.001547},"volumeRatio":0.24055753961271284,"impliedVol":0.1361,"impliedVolPercentile":0.3386},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","floatShares":7250270,"roa":"0.26%","roe":"42.40%","lyrEps":-0.128016,"volumeRatio":0.24055753961271284,"shares":7250270,"dividePrice":0.2736,"high":65.03,"amplitude":0.023417,"preClose":63.63,"low":63.54,"week52Low":46.9,"pbRate":"1.09","psRate":"213.95","week52High":74.345,"institutionHeld":0,"latestPrice":64.65,"eps":2.581957,"divideRate":0.004232,"volume":82544,"delay":0,"ttmEps":2.581957,"open":63.64,"prevYearClose":56.01,"prevWeekClose":63.64,"prevMonthClose":65,"prevQuarterClose":65,"fiveDayClose":63.64,"twentyDayClose":67.51,"sixtyDayClose":67.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XPH\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"XPH","amount":0.04164,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-23","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-23"},{"date":"2026-06-22","symbol":"XPH","amount":0.059045,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XPH","amount":0.060954,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XPH","amount":0.113024,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XPH","amount":0.102634,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.091273,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.026956,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.085023,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.07227,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.019429,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XPH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1147221461","title":"Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, \"Buy\" Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1147221461","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147221461?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:54","pubTimestamp":1790672068,"startTime":"0","endTime":"0","summary":"Citi issued a research report stating that Sino Biopharmaceutical (01177), through its subsidiary Chia Tai Tianqing, has entered into a strategic partnership with German pharmaceutical company STADA...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0648001328.SGD","LU2322448791.USD","LU1162221912.USD","01177","LU1791807156.HKD","LU0320765646.SGD","LU1244550494.USD","LU1244550221.USD","IE00BZ08YS42.EUR","LU2322448957.HKD","LU2236285917.USD","LU2125154778.USD","LU1201861249.SGD","FTXO","BK1191","BK1515","LU0052756011.USD","LU2360032135.SGD","BK4207","LU2272731600.USD","BK4566","LU0203347892.USD","BK4585","LU1144417596.USD","LU1992135399.USD","LU2272731782.SGD","BK4559","BK4588","LU0106831901.USD","HK0000165453.HKD","LU0310800965.SGD","PPH","LU0098860793.USD","LU0162691827.USD","LU1506573853.SGD","LU0203345920.USD","LU2417539215.USD","IE00B5TLWC47.USD","LU0128525689.USD","XPH","LU0130517989.USD","TFNS","C","IE00BZ08YT58.USD","LU2473716301.USD","BK4534","BK1521","LU0477156953.USD","LU1244550577.SGD","LU0980610538.SGD","IBB","IE00BSNM7G36.USD","LU2272731865.HKD","LU1992135472.HKD","LU1366192091.USD","LU1668664300.SGD","LU0170899867.USD","LU2125154935.USD","LU2456880835.USD","IE00BZ08YR35.GBP","BK1589","LU1074936037.SGD","LU0130102774.USD","BK4504","LU2462157665.USD","IYF","LU0314106906.USD","LU1267930227.SGD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188705505","title":"Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705505","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705505?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:03","pubTimestamp":1790647387,"startTime":"0","endTime":"0","summary":"Shares of Sino Biopharmaceutical (01177) climbed nearly 4%, rising 3.64% to HK$5.695 as of press time, with turnover reaching HK$89.7588 million.On the news front, Sino Biopharmaceutical announced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","BK1521","MEURmain","VXUS","IE00BZ08YT58.USD","FXE","BK4588","LU2473716301.USD","LU1992135399.USD","LU2322448957.HKD","IE00BZ08YS42.EUR","KCAI","EUO","HK0000165453.HKD","BK1589","NBIE","LU2322448791.USD","LU2272731865.HKD","LU2272731600.USD","LU1992135472.HKD","IBB","BK1515","XPH","01177","IE00BZ08YR35.GBP","EURmain","PPH","BK4585","LU2272731782.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131230465","title":"Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1131230465","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131230465?lang=en_us&edition=fundamental","pubTime":"2026-09-18 09:54","pubTimestamp":1789696466,"startTime":"0","endTime":"0","summary":"A recent industry analysis warns that over the next decade, nearly 90% of biologic drugs losing their market exclusivity will lack a corresponding biosimilar in development, creating a significant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","BK4588","LU2272731782.SGD","LU2322448957.HKD","LU2322448791.USD","IBB","LU1992135472.HKD","LU2473716301.USD","PPH","BK4585","LU2272731865.HKD","XPH","LU2272731600.USD","IE00B5TLWC47.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188259168","title":"Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14","url":"https://stock-news.laohu8.com/highlight/detail?id=1188259168","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188259168?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:50","pubTimestamp":1789120228,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that the drug registration application for its self-developed denosumab biosimilar, HLX14 (recombinant anti-RANKL fully human...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU2473716301.USD","LU1992135399.USD","PPH","IBB","BK0188","BK0028","BK0196","IE00B5TLWC47.USD","BK0096","BK0060","XPH","BK0187","02196","BK4585","LU2322448791.USD","BK0239","BK0175","BK1515","LU1992135472.HKD","BK0012","LU2272731782.SGD","BK4588","LU2272731600.USD","LU2322448957.HKD","BK1593","LU2272731865.HKD","600196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731600.USD","IBBQ","BK1574","BK4585","BK4588","LU2272731865.HKD","HK0000306685.HKD","HK0000165453.HKD","LU1992135399.USD","LU2322448957.HKD","MEDX","LU2473716301.USD","IBB","LU2272731782.SGD","159992","BK1161","LU1992135472.HKD","LNGR","06978","XPH","IE00B5TLWC47.USD","HK0000320264.USD","LU2322448791.USD","PPH","HK0000320223.HKD","HK0000306701.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","MDTX","MNTL","FHLC","BBH","HYLG","BBP","CURE","CNCR","SURI","SYNB","IBBJ","XPH","FBT","JDOC","NVIB","GNOM","MEDX","SBIO","PSCH","APXH","PJP","AZNH","PBE","PTH","IBB","BME","TBXU","GDOC","IBBQ","PSIL","IDNA","IBRN","RSPH","MEDI","IEIH","MRNY","CANC","JHMH","LFSC","PINK","HRTS","LLYX","GNMX","PBPH","GPCR","BIB","FTXH","WDNA","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","PBE","FHLC","SURI","PINK","RSPH","PBPH","APXH","IDNA","BIB","HRTS","GNMX","IBBJ","IBRN","NVIB","HYLG","GSKH","GPCR","BBH","PSIL","XPH","PJP","MDTX","MEDI","JDOC","CNCR","FBT","LLYX","FXH","JHMH","WDNA","SYNB","FTXH","MNTL","MEDX","PSCH","LENZ","CURE","GDOC","IBB","MRNY","BBP","GNOM","LFSC","TBXU","PTH","SBIO","IBBQ","CANC","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191429118","title":"Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars","url":"https://stock-news.laohu8.com/highlight/detail?id=1191429118","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191429118?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:00","pubTimestamp":1787194818,"startTime":"0","endTime":"0","summary":"Shares of HENLIUS (02696) climbed nearly 8% during intraday trading, with the stock last up 6.87% at HK$70.05, recording a turnover of HK$16.47 million. The company recently announced a framework...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2322448791.USD","HK0000165453.HKD","LU1992135472.HKD","HK0000306701.USD","02696","IBB","BK4585","XPH","LU2473716301.USD","LU2272731600.USD","BK4588","LU2322448957.HKD","LU2272731782.SGD","HK0000320223.HKD","HK0000320264.USD","LU2272731865.HKD","HK0000306685.HKD","PPH","IE00B5TLWC47.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492411","title":"BMO starts Exelixis at Market Perform into patent cliff","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492411?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:30","pubTimestamp":1787085023,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durabl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","FTXH","BK4207","PTH","BBH","MEDI","TMED","LU2272731782.SGD","BK4588","EXEL","FHLC","RXD","SYNB","FXH","PJP","BME","MEDX","PBPH","IE00B5TLWC47.USD","FBT","PPH","XPH","APXH","BMO","TRUH","AZNH","GSKH","IBB","LU2322448957.HKD","BK4585","LU2322448791.USD","CURE","BK4532","LU2272731600.USD","IHE","RSPH","JDOC","RXL","LU1992135399.USD","LU2473716301.USD","BK4139","LU1992135472.HKD","LU2272731865.HKD","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167771958","title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1167771958","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167771958?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:33","pubTimestamp":1785713585,"startTime":"0","endTime":"0","summary":"AstraZeneca PLC (AZN.US) has been in early-stage discussions about acquiring Bristol-Myers Squibb (BMY.US), a move that could create one of the world's largest pharmaceutical companies, according to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0096364046.USD","MEDI","LU0128525929.USD","LU1992135472.HKD","LU0306806265.USD","LU1718418525.SGD","LU0061475181.USD","LU1323610961.USD","LU1829250122.USD","LU1883839398.USD","LU2236285917.USD","LU2237443622.USD","LU0109394709.USD","BK4585","LU1291159041.SGD","LU1989771016.USD","LU0320765992.SGD","BK4581","IE00BSNM7G36.USD","LU2417539215.USD","LU2237443895.HKD","LU1983299246.USD","RXL","FTXH","IEHS","LU1267930573.SGD","IE0002141913.USD","LU1032466523.USD","LU0432979614.USD","CURE","LU2596442595.SGD","LU2125154778.USD","LU2272731600.USD","IE0009355771.USD","JHMH","LU2242646821.SGD","BK4007","IE00BFXG1179.USD","PPH","LU1868836914.USD","IE00BJJMRZ35.SGD","BK4532","LU1571399168.USD","LU0868494617.USD","LU0114720955.EUR","LU0889565916.HKD","LU1868837300.USD","XBIX","LU1992135399.USD","LU1093756325.SGD","LU2322448957.HKD","AZN","IE00BFTCPJ56.SGD","LU0225284248.USD","LU0237698245.USD","LU1670711123.USD","PILL","BK4568","LU1093756168.USD","LU2133065610.SGD","IE00B3T34201.USD","BMY","LU2456880835.USD","FXH","LU1585245621.USD","LU2360032135.SGD","LU2272731865.HKD","LU2462157665.USD","LU2322448791.USD","BK4534","LU1670711040.USD","LU2089984988.USD","LU0058720904.USD","LU0985481810.HKD","LU0310800379.SGD","LU2125154935.USD","LU2242652126.USD","LU2272731782.SGD","LU0306807586.USD","AZNH","IE00B5TLWC47.USD","BK4588","LU2237443978.SGD","LU0225771236.USD","LU0708994859.HKD","LU1868836591.USD","LU2468319806.SGD","XPH","LU0267386448.USD","LU1670710588.SGD","LU0456855351.SGD","LU1430594728.SGD","LU1261432733.SGD","RXD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU0029864427.USD","IHE","FHLC","LU2237443465.HKD","LU0321505439.SGD","LU2473716301.USD","LU2237443549.SGD","LU1670710661.SGD","LU1868836757.USD","IE00B2B36J28.USD","LU1868837136.USD","BK4559","SYNB","LU2237443382.USD","LU1074936037.SGD","LU0289739699.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122606361","title":"HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1122606361","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122606361?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:32","pubTimestamp":1783503169,"startTime":"0","endTime":"0","summary":"HENLIUS (ASX: 02696) has announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1 clinical study of its self-developed cetuximab injection...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","LU2322448957.HKD","LU2272731600.USD","BK1161","LU1992135399.USD","HK0000320264.USD","HK0000320223.HKD","IE00B5TLWC47.USD","HK0000306701.USD","LU1992135472.HKD","LU2473716301.USD","LU2272731782.SGD","IBB","HK0000165453.HKD","HK0000306685.HKD","LU2322448791.USD","BK4588","BK4585","PPH","LU2272731865.HKD","XPH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}